Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19-.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciae105 | DOI Listing |
Publication Analysis
Top Keywords
combined protection
4
protection vaccination
4
vaccination nirmatrelvir-ritonavir
4
nirmatrelvir-ritonavir hospitalization
4
hospitalization adults
4
adults covid-19
4
covid-19 adults
4
adults risk
4
risk severe
4
severe coronavirus
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!